An EGFR wild type–EGFRvIII–HB-EGF feed-forward loop regulates the activation of EGFRvIII

[1]  S. Burma,et al.  Opposing effect of EGFRWT on EGFRvIII-mediated NF-κB activation with RIP1 as a cell death switch. , 2013, Cell reports.

[2]  J. Pollack,et al.  EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms , 2013, Oncogene.

[3]  S. Hariono,et al.  Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. , 2012, Cancer discovery.

[4]  Paul S Mischel,et al.  Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. , 2012, Cancer discovery.

[5]  J. Sarkaria,et al.  Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. , 2011, The Journal of clinical investigation.

[6]  D. Housman,et al.  Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation. , 2011, Cancer research.

[7]  O. Bogler,et al.  Cancer Genes and Genomics Forced Dimerization Increases the Activity of D EGFR / EGFRvIII and Enhances Its Oncogenicity , 2011 .

[8]  S. Lawler,et al.  The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells , 2011, Journal of Neuro-Oncology.

[9]  S. Burma,et al.  Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance. , 2010, Neoplasia.

[10]  Yoshitaka Narita,et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.

[11]  J. Rak,et al.  Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. , 2010, Blood.

[12]  Derek Toomre,et al.  Spatial control of EGF receptor activation by reversible dimerization on living cells , 2010, Nature.

[13]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[14]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[15]  Forest M White,et al.  Oncogenic EGFR Signaling Networks in Glioma , 2009, Science Signaling.

[16]  A. Scott,et al.  The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. , 2009, Neoplasia.

[17]  D. Housman,et al.  Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis , 2009, Proceedings of the National Academy of Sciences.

[18]  K. Ferguson,et al.  Structure-based view of epidermal growth factor receptor regulation. , 2008, Annual review of biophysics.

[19]  P. Wright,et al.  RIP1 links inflammatory and growth factor signaling pathways by regulating expression of the EGFR , 2008, Cell Death and Differentiation.

[20]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[21]  Forest M White,et al.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.

[22]  A. Scott,et al.  The Efficacy of Epidermal Growth Factor Receptor–Specific Antibodies against Glioma Xenografts Is Influenced by Receptor Levels, Activation Status, and Heterodimerization , 2007, Clinical Cancer Research.

[23]  Patrick Y Wen,et al.  Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. , 2006, The oncologist.

[24]  Kimmo J Hatanpaa,et al.  Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. , 2006, Cancer research.

[25]  W. Cavenee,et al.  Immunohistochemical analysis of the mutant epidermal growth factor, ΔEGFR, in glioblastoma , 2006, Brain Tumor Pathology.

[26]  Koji Yoshimoto,et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.

[27]  Qian Wang,et al.  Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation , 2005, EMBO reports.

[28]  L. Gunaratnam,et al.  Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. , 2005, Cancer research.

[29]  A. Scott,et al.  The tumor-specific de2–7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR , 2004, Oncogene.

[30]  P. Kleihues,et al.  Predominant Expression of Mutant EGFR (EGFRvIII) is Rare in Primary Glioblastomas , 2004, Brain pathology.

[31]  A. Dowlati,et al.  Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. , 2004, Molecular cancer therapeutics.

[32]  R. Jove,et al.  Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells , 2003, International journal of cancer.

[33]  Edouard C. Nice,et al.  Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.

[34]  J. Schlessinger.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[35]  Careen K. Tang,et al.  Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. , 2000, Cancer research.

[36]  H. Varmus,et al.  A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. , 1998, Genes & development.

[37]  K. Mishima,et al.  Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas , 1998, Acta Neuropathologica.

[38]  H. Wiley,et al.  The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling* , 1997, The Journal of Biological Chemistry.

[39]  O. Bogler,et al.  A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.

[40]  R. B. Montgomery,et al.  Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. , 1996, Oncogene.

[41]  P. Humphrey,et al.  Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[42]  W. Cavenee,et al.  A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Barrett,et al.  Immunocytochemical study of transforming growth factor expression in benign and malignant gliomas. , 1989, The American journal of pathology.

[44]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.